Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

489 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor recurrence after oLTX.
Gruenberger T, Windhager T, Gnant M, Mittlböck M, Steininger R, Herbst F, Muehlbacher F. Gruenberger T, et al. Among authors: gnant m. Transpl Int. 1996;9 Suppl 1:S151-4. doi: 10.1007/978-3-662-00818-8_37. Transpl Int. 1996. PMID: 8959813
Dendritic cell-based vaccination in solid cancer.
Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Schueller G, Zontsich T, Benkoe T, Radelbauer K, Brostjan C, Jakesz R, Gnant M. Stift A, et al. Among authors: gnant m. J Clin Oncol. 2003 Jan 1;21(1):135-42. doi: 10.1200/JCO.2003.02.135. J Clin Oncol. 2003. PMID: 12506182 Clinical Trial.
Monocyte subsets in breast cancer patients under treatment with aromatase inhibitor and mucin-1 cancer vaccine.
Knöbl V, Maier L, Grasl S, Kratzer C, Winkler F, Eder V, Hayden H, Sahagun Cortez MA, Sachet M, Oehler R, Frantal S, Fesl C, Zehetner K, Pfeiler G, Bartsch R, Fitzal F, Singer CF, Filipits M, Gnant M, Brostjan C. Knöbl V, et al. Among authors: gnant m. J Transl Med. 2024 Oct 8;22(1):913. doi: 10.1186/s12967-024-05659-w. J Transl Med. 2024. PMID: 39380101 Free PMC article.
• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected.
Kappel-Latif S, Zacherl J, Hejna M, Westerhoff M, Tamandl D, Ba-Ssalamah A, Mittlböck M, Wolf B, Wrba F, Kührer I, Pluschnig U, Schoppmann SF, Függer R, Zwrtek R, Glaser K, Karner J, Längle F, Wenzl E, Roka R, Öfner D, Tschmelitsch J, Hold M, Keil F, Gnant M, Kandioler D; Pancho trialists and for the Medical University of Vienna p53research group. Kappel-Latif S, et al. Among authors: gnant m. Eur Surg. 2018;50(4):160-166. doi: 10.1007/s10353-018-0527-z. Epub 2018 Jun 11. Eur Surg. 2018. PMID: 30559831 Free PMC article.
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C, Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R. Michlmayr A, et al. Among authors: gnant m. Br J Cancer. 2010 Oct 12;103(8):1201-8. doi: 10.1038/sj.bjc.6605909. Epub 2010 Sep 28. Br J Cancer. 2010. PMID: 20877360 Free PMC article. Clinical Trial.
489 results